XECHEM WILL PARTICIPATE AT WALL STREET ANALYST FORUM CONFERENCE, SEPTEMBER 10, 2002

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

SUBSCRIBE/UNSUBSCRIBE |

Conservation & Wildlife

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

FOR IMMEDIATE RELEASE

XECHEM WILL PARTICIPATE AT WALL STREET ANALYST FORUM CONFERENCE, SEPTEMBER 10, 2002

NEW JERSEY, NEW BRUNSWICK, Aug. 22 -/E-Wire/-- Xechem International, Inc. (OTC BB: ZKEM) announced that it has accepted an invitation from the Wall Street Analyst Forum, Institutional Investor Conferences to provide a presentation of Xechem's recent drug discoveries and acquisitions, most notably its new drug management for sickle cell anemia disease.

At this conference the heads of one hundred leading NYSE/NASDAQ/AMEX corporations will provide presentations, with over 800 analyst/portfolio managers expected to attend, as well as thousands of investors who will participate world-wide via global web cast (CCBN). Some notable industry leader attendees include SmithKline Beecham, Inc., Chiron Corporation and Biopure Corporation.

According to Xechem's President & CEO, Dr. Ramesh C. Pandey, "This exciting and fortuitous conference will provide Xechem an unparalleled opportunity to inform many industry leaders of Xechem's extensive pharmaceutical products portfolio and technical expertise, and will allow us to reach institutional investors and potential partners on an international level. Stock prices may fluctuate, but quality, innovative and much needed drugs are always in increasing demand. This is our chance to show the world what Xechem has, and what we can do for millions of patients in need."

Xechem International, Inc., headquartered in New Brunswick, NJ, with subsidiary companies in the USA, India, Nigeria and joint venture partners in both Hong Kong and the Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer, antiviral, including Human Immuno-deficiency Virus (HIV) and antifungal compounds. Xechem is also engaged in the research and development of several novel anti-infectives showing strong and selective efficacy against an array of antibiotic resistant bacterias, including Helicobacter pylori (H. pylori), Vancomycin resistant Enterococcus faecalis (VREF), Methicillin resistant Staphylococcus aureus (MRSA), and other antibiotic resistant Staphylococcus aureus and Candida albicans. The Company also screens extracts and pure compounds from various parts of the world for their therapeutic use.

XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products such as GinkgoOnceÂ®, GinsengOnceÂ®, GarlicOnceÂ®, Gugulonâ¢, VIDA PRASâ¢ and numerous other nutraceutical products, which are under development.

This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.

For further information, contact the President and Chief Executive Officer, Dr. Ramesh C. Pandey at (732) 247 - 3300.

This news release may contain certain forward-looking statements relating to Xechem's future business performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.

Xechem International, Inc.

Dr. Ramesh C. Pandey at (732) 247 - 3300.

http://www.xechem.com

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************